Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 29
---
 placement agent and prospective investors, and may not be indicative
of prices that will prevail in the trading market. We do not intend to apply to list the warrants on NASDAQ or any nationally recognized
trading system, and accordingly, there will be no trading market for such warrants. In the absence of an active public trading market:

| · | you may not be able to resell your securities at or above the public offering price; |

| · | the market price of our Depositary Shares may experience more price volatility; and |

| · | there may be less efficiency in carrying out your purchase and sale orders. |

| 18 |

Holders of Pre-Funded Warrants and Series L Warrants purchased in this offering will have no rights as Depositary Share holders until such holders exercise such Pre-Funded Warrants and Series L Warrants and acquire our Depositary Shares.

Until holders of Pre-Funded
Warrants and Series L Warrants acquire Depositary Shares upon exercise of such Pre-Funded Warrants and Series L Warrants, holders of Pre-Funded
Warrants and Series L Warrants will have no rights with respect to the Depositary Shares underlying such Pre-Funded Warrants and Series
L Warrants. Upon exercise of the Pre-Funded Warrants and Series L Warrants, as applicable, the holders will be entitled to exercise the
rights of an Depositary Share holder only as to matters for which the record date occurs after the exercise date.

The Pre-Funded Warrants and Series L Warrants are speculative in nature.

The Pre-Funded Warrants and
Series B Warrants do not confer any rights of Depositary Share ownership on their respective holders, such as voting rights or the right
to receive dividends, but rather merely represent the right to acquire Depositary Shares at a fixed price.

The Series L Warrants may not have value.

The Series L Warrants being offered by us
in this offering will have an initial exercise price of 225% of the public offering price of each Unit in this offering, and expire on
the two and a half--year anniversary of the initial exercise date. In the event that our Depositary Shares do not exceed the exercise
price of the Series L Warrants during the period when such warrants are exercisable, such warrants may not have any value.

The terms of the warrants could impede our ability to enter into certain transactions or obtain additional financing.

The terms of the warrants
require us, upon the consummation of any “fundamental transaction”